We read with great interest the article "Effectiveness and safety of adalimumab biosimilar ABP 501 in Crohn's disease: an observational study" by Ribaldone et al., which was recently published in your journal. The authors report the first real-life study of the adalimumab biosimilar ABP 501 in Crohn's disease (CD). The study investigated the short-term effectiveness and safety of ABP 501 in 87 patients with CD, 25 patients naïve to adalimumab and 62 switched from the adalimumab originator. A meaningful proportion of CD patients treated with ABP 501 showed clinical benefit with a satisfactory safety profile until the end of follow-up.
|Titolo:||Effectiveness and safety of switching to adalimumab biosimilar ABP 501 in Crohn's disease|
VISCIDO, Angelo (Corresponding)
|Data di pubblicazione:||2021|
|Appare nelle tipologie:||1.1 Articolo in rivista|